Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1362942 | Bioorganic & Medicinal Chemistry Letters | 2010 | 6 Pages |
Abstract
The discovery and optimization of a series of pyrrolopyrimidine based protein kinase B (Pkb/Akt) inhibitors discovered via HTS and structure based drug design is reported. The compounds demonstrate potent inhibition of all three Akt isoforms and knockdown of phospho-PRAS40 levels in LNCaP cells and tumor xenografts.
Graphical abstractThe discovery and optimization of a series of pyrrolopyrimidine based protein kinase B (Pkb/Akt) inhibitors discovered via HTS and structure based drug design is reported. The compounds demonstrate potent inhibition of all three Akt isoforms and knockdown of phospho-PRAS40 levels in LNCaP cells and tumor xenografts.Figure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
James F. Blake, Nicholas C. Kallan, Dengming Xiao, Rui Xu, Josef R. Bencsik, Nicholas J. Skelton, Keith L. Spencer, Ian S. Mitchell, Richard D. Woessner, Susan L. Gloor, Tyler Risom, Stefan D. Gross, Matthew Martinson, Tony H. Morales, Guy P.A. Vigers,